These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

285 related articles for article (PubMed ID: 19407174)

  • 21. Biogen Idec restructures, sharpens neurology focus.
    Mitchell P
    Nat Biotechnol; 2011 Jan; 29(1):7-8. PubMed ID: 21221080
    [No Abstract]   [Full Text] [Related]  

  • 22. A place in the sun.
    Abbott A
    Nature; 2007 Mar; 446(7132):124-5. PubMed ID: 17344823
    [No Abstract]   [Full Text] [Related]  

  • 23. Growing against the grain.
    Boyle M
    Fortune; 2004 May; 149(9):148-9, 152, 154 passim. PubMed ID: 15124331
    [No Abstract]   [Full Text] [Related]  

  • 24. Conclusions: promoting biotechnology innovation in developing countries.
    Thorsteinsdóttir H; Quach U; Daar AS; Singer PA
    Nat Biotechnol; 2004 Dec; 22 Suppl(Suppl 12):DC48-52. PubMed ID: 15583685
    [No Abstract]   [Full Text] [Related]  

  • 25. An Audience with... Interview by Bethan Hughes.
    Chin W
    Nat Rev Drug Discov; 2010 May; 9(5):354. PubMed ID: 20431560
    [No Abstract]   [Full Text] [Related]  

  • 26. In search of the élite.
    Gewin V
    Nature; 2003 Dec; 426(6967):713-7. PubMed ID: 14668879
    [No Abstract]   [Full Text] [Related]  

  • 27. Genentech grapples with direct offer.
    Huggett B
    Nat Biotechnol; 2009 Mar; 27(3):212. PubMed ID: 19270652
    [No Abstract]   [Full Text] [Related]  

  • 28. Stuck in the middle.
    Fuyuno I
    Nature; 2006 Jul; 442(7100):237. PubMed ID: 16855561
    [No Abstract]   [Full Text] [Related]  

  • 29. The science-business tango. Interview by Mari Paul.
    Hirth P
    Nat Biotechnol; 2006 Aug; 24(8):1035-6. PubMed ID: 16900153
    [No Abstract]   [Full Text] [Related]  

  • 30. Glyn Edwards talks about cancer drug development at Antisoma. Interview by Ulrike Knies-Bamforth and Dan Huke.
    Edwards G
    Drug Discov Today; 2005 Nov; 10(22):1491-4. PubMed ID: 16257369
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Research not fit to print.
    Nat Biotechnol; 2016 Feb; 34(2):115. PubMed ID: 26849496
    [No Abstract]   [Full Text] [Related]  

  • 32. Back on target.
    Webb S
    Nat Biotechnol; 2013 Mar; 31(3):191-3. PubMed ID: 23471062
    [No Abstract]   [Full Text] [Related]  

  • 33. Newsmaker interview. A civil conversation about animals in research. Interview by Greg Miller.
    Ringach D
    Science; 2010 Mar; 327(5971):1315. PubMed ID: 20223960
    [No Abstract]   [Full Text] [Related]  

  • 34. Isis and antisense face crucial test without Novartis.
    Dove A
    Nat Biotechnol; 2000 Jan; 18(1):19. PubMed ID: 10625379
    [No Abstract]   [Full Text] [Related]  

  • 35. [Merck & Co: Lakartidningen is wrong about us].
    Ringart T
    Lakartidningen; 2008 Nov 12-18; 105(46):3358; author reply 3358-9. PubMed ID: 19062629
    [No Abstract]   [Full Text] [Related]  

  • 36. Best of both worlds.
    Smaglik P
    Nature; 2003 Dec; 426(6967):706-7. PubMed ID: 14668875
    [No Abstract]   [Full Text] [Related]  

  • 37. I see you've worked at Merck ..
    Mervis J
    Science; 2005 Jul; 309(5735):727. PubMed ID: 16051785
    [No Abstract]   [Full Text] [Related]  

  • 38. Private development companies: transforming academic research into new treatment options for cancer.
    Janoff AS
    Mol Interv; 2010 Apr; 10(2):65-8. PubMed ID: 20368364
    [No Abstract]   [Full Text] [Related]  

  • 39. Portfolio analysis and R&D decision making.
    Evans R; Hinds S; Hammock D
    Nat Rev Drug Discov; 2009 Mar; 8(3):189-90. PubMed ID: 19182818
    [No Abstract]   [Full Text] [Related]  

  • 40. Drug companies and neuroprotection of the newborn: any hope for a love story?
    Gressens P
    Acta Paediatr; 2007 Apr; 96(4):485-6. PubMed ID: 17391464
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.